LisaVermunt Profile Banner
Lisa Vermunt Profile
Lisa Vermunt

@LisaVermunt

Followers
397
Following
634
Media
20
Statuses
558

@AlzheimerAms | MD | PhD | biofluid biomarkers | autosomal dominant Alzheimer | proteomics | disease modelling | clinical trials

Amsterdam, Nederland
Joined May 2014
Don't wanna be here? Send us removal request.
@LisaVermunt
Lisa Vermunt
3 years
🙏Equally excited to share plasma glial fibrillary acidic protein (#GFAP) in #DIAN! 👉 see: https://t.co/EcPMyE5Xvw @alzdemjournals 👉 or go for the summary below by my dear co-author @PratishthaChat7 @AlzheimerAms @Alz_onderzoek @AmsNeuroscience #stichtingdioraphte
@PratishthaChat7
Pratishtha Chatterjee
3 years
(1/6) Excited that our paper on plasma glial fibrillary acidic protein (#GFAP) in dominantly inherited #AlzheimersDisease is now out👉 https://t.co/fgWHENqkBr. @alzdemjournals. 🙏Many thanks @LisaVermunt @BrianGordon81 @RalphNMartins1 @CharlotteTeuni1 and all collaborators!
0
4
11
@BrianGordon81
Brian Gordon
2 years
Out now in @braincomms. Worked started over two years ago by @karin_meeker examining the relationship between 27 different AD biomarkers including MRI, PET, mass-spec, and plasma measures.
academic.oup.com
Meeker et al. use machine learning methods on 27 plasma, CSF, MRI and PET Alzheimer’s disease biomarkers to demonstrate that although the number of Alzheim
2
13
38
@LisaVermunt
Lisa Vermunt
2 years
@LisaVermunt
Lisa Vermunt
2 years
The dream of #biomarker #discovery with #proteomics - check out our preprint with our novel, replicable, mechanistically logical protein biomarkers in #CSF for #DLB https://t.co/XjnPR8DPBT @AlzheimerAms @AmsNeuroscience @BarcelonaBeta Del Campo,@CharlotteTeuni1 and others
0
0
6
@LisaVermunt
Lisa Vermunt
2 years
The dream of #biomarker #discovery with #proteomics - check out our preprint with our novel, replicable, mechanistically logical protein biomarkers in #CSF for #DLB https://t.co/XjnPR8DPBT @AlzheimerAms @AmsNeuroscience @BarcelonaBeta Del Campo,@CharlotteTeuni1 and others
0
2
4
@AlzheimerAms
Alzheimercentrum Amsterdam (inactief)
2 years
NWO vroeg aan 5 wetenschappers welke oproep zij aan de #politiek doen op #Prinsjesdag. Onderzoeker @LisaVermunt van @AlzheimerAms wil overbrengen hoe belangrijk kennis is. “Zonder wetenschap geen nieuwe medicijnen.” Lees alle oproepen: https://t.co/hRZePxzMSR @NWONieuws
0
1
2
@LisaVermunt
Lisa Vermunt
2 years
Very grateful for my #Veni grant! A boost for our research line on familial #AD. By tracing #astrocyte failure with #laboratory tests, we will better understand how #Alzheimer evolves, to further precise forecasting and faster treatments. @ZonMw @AlzheimerAms @AmsNeuroscience
@NWOFunding
NWO Funding
2 years
NWO has awarded Veni funding of up to EUR 280,000 to 188 promising researchers from the full breadth of science. This will allow the laureates to further develop their own research ideas over the next three years. https://t.co/tUCSbytmva
6
1
20
@alzforum
Alzforum
2 years
A trio of studies make a strong case that SORL1 is the fourth familial Alzheimer’s gene. @AarhusUni @amsterdamumc
1
2
16
@LisaVermunt
Lisa Vermunt
2 years
The dream of #biomarker #discovery with #proteomics - check out our preprint with our novel, replicable, mechanistically logical protein biomarkers in #CSF for #DLB https://t.co/XjnPR8DPBT @AlzheimerAms @AmsNeuroscience @BarcelonaBeta Del Campo,@CharlotteTeuni1 and others
0
2
4
@LisaVermunt
Lisa Vermunt
2 years
With shared pathophysiological CSF changes, ADAD study findings might be translatable to sporadic AD, which could greatly expedite therapy development.
0
0
1
@LisaVermunt
Lisa Vermunt
2 years
This CSF proteomics study demonstrates substantial biochemical similarities between ADAD and sporadic AD, suggesting involvement of the same biological processes. We identified several relatively novel proteins, which have potential as novel biomarkers.
1
0
1
@ccrugom
Carlos Cruchaga
2 years
Our latest publication: Proteomics of brain, CSF, and plasma identifies molecular signatures for distinguishing sporadic and genetic Alzheimer’s disease https://t.co/qn4MX3Y76F @WUADRC @Neuro_Genomics @WashUNeurology
Tweet card summary image
science.org
Proteomics of brain, CSF, and plasma identifies markers that distinguish sporadic AD from autosomal dominant AD (ADAD) and TREM2 risk carriers.
1
14
62
@jmschott
Jonathan Schott
3 years
Breaking news: @EliLillyandCo Phase 3 trial of Donanemab is positive, showing significant slowing on cognitive and functional outcomes. Now we have two positive trials showing effects of amyloid clearance in Alzheimer's disease-- hugely exciting times! https://t.co/pgpm34UMmv
0
43
111
@braincomms
@BrainComms
3 years
Van Engelen et al. report that the use of urine as a matrix for neurofilament light chain (NfL) analysis to differentiate frontotemporal dementia from psychiatric disorders is not suitable and that urine NfL levels did not correlate with serum levels. https://t.co/vR9RMXUN9R
0
4
13
@karchlab
Celeste Karch
3 years
I’m VERY excited to share our latest work with ⁦@LauraPiccio⁩. Led by the brilliant ⁦@FabiaFilipello⁩ identifying defects in iPSC-microglia from Nasu Hakola patients that were restored by targeting mTOR dependent and independent pathways ⁦
link.springer.com
Acta Neuropathologica - TREM2 is an innate immune receptor expressed by microglia in the adult brain. Genetic variation in the TREM2 gene has been implicated in risk for Alzheimer’s disease...
5
32
110
@LisaVermunt
Lisa Vermunt
3 years
Biological enrichment for cell signalling and immune response pathways, with lower levels in fast progressing patients. Taken together, we present a novel progression biomarker identification framework and protein leads for prediction of cognitive decline in dementia.
0
0
0
@LisaVermunt
Lisa Vermunt
3 years
#TNFRSF4 and #TGF ββ-1 emerged as the top markers, being lower in fast-progressing patients compared to slow-progressing patients. None of our top markers stood out as strong individual predictors of subsequent #cognitive #decline.
1
0
0
@LisaVermunt
Lisa Vermunt
3 years
👉 paper alert! Providing an accurate #prognosis for individual #dementia patients remains a challenge. We used machine learning techniques to identify #CSF #biomarkers that predict decline. https://t.co/mT55rfD7p4 @AmsNeuroscience @AlzheimerAms @CharlotteTeuni1 @OlinkProteomics
Tweet card summary image
nature.com
Scientific Reports - Discovery of novel CSF biomarkers to predict progression in dementia using machine learning
2
3
11